This is the authors' abstract. We don't add key points for this paper.
As a group, patients with normal tension glaucoma benefit from lowering of IOP. Variable rate of deterioration, as well as lack of progression in a substantial number in 5 years, suggest that treatment should be individualized according to the stage of disease and rate of progression. Traits that help predict risk and rate of progression and response to treatment are beginning to become known and, when fully known, will help guide management decisions.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Douglas R. Anderson (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: